TTT Stock UPDATES Ultrapro Short 20+ Year Trsy Proshares (TTT)

New Post Public Reply Private Reply Replies (0) Message Board

Sep 17, 2014 at 10:04 AM

Ultrapro Short 20+ Year Trsy Proshares (TTT) 60.83 $TTT

10.4% Return Seen to Date on SmarTrend Terra Nova Royalty Call (TTT)
Comtex SmarTrend(R) - Fri Sep 05, 5:21PM CDT
SmarTrend identified a Downtrend for Terra Nova Royalty (NYSE:TTT) on June 25th, 2014 at $64.28. In approximately 2 months, Terra Nova Royalty has returned 10.37% as of today's recent price of $57.61.

Shares of TTT Down 17.4% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Aug 29, 11:11AM CDT
SmarTrend identified a Downtrend for Terra Nova Royalty (NYSE:TTT) on June 25th, 2014 at $64.28. In approximately 2 months, Terra Nova Royalty has returned 17.41% as of today's recent price of $53.09.

ProShares Launches MSCI EAFE Dividend Growers ETF (EFAD)
Business Wire - Thu Aug 21, 8:01AM CDT
ProShares, a premier provider of alternative ETFs, today launched the ProShares MSCI EAFE Dividend Growers ETF (EFAD), the first ETF that invests in the companies in the MSCI EAFE Index with the best track record of consistent year-over-year dividend growth. EFAD, which is listed on NYSE Arca, tracks the MSCI EAFE Dividend Masters Index.

Downtrend Call Working As Terra Nova Royalty Stock Falls 12.0% (TTT)
Comtex SmarTrend(R) - Fri Aug 15, 9:29AM CDT
SmarTrend identified a Downtrend for Terra Nova Royalty (NYSE:TTT) on June 25th, 2014 at $64.28. In approximately 2 months, Terra Nova Royalty has returned 11.98% as of today's recent price of $56.58.

ProShares Investment Grade--Interest Rate Hedged ETF Surpasses $100 Million in Assets
Business Wire - Mon Aug 11, 8:01AM CDT
ProShares, a premier provider of alternative exchange traded funds, today announced that Investment Grade--Interest Rate Hedged ETF (IGHG) has surpassed $100 million in assets. Launched in November 2013, IGHG delivers a diversified portfolio of investment grade bonds with a built-in interest rate hedge.

ProShares Launches ETFs Offering "Pure" Exposure to High Yield Credit
Business Wire - Thu Aug 07, 8:01AM CDT
ProShares, a premier provider of alternative ETFs, today launched two funds that provide pure exposure to the credit component of the high yield bond market uncoupled from the interest rate component. ProShares CDS North American HY Credit ETF (TYTE) and ProShares CDS Short North American HY Credit ETF (WYDE) are listed on the BATS exchange.

ProShares Launches First "Pure-Play" Infrastructure ETF
Business Wire - Thu Mar 27, 7:30AM CDT
ProShares, a premier provider of alternative exchange traded funds, today announced the launch of the ProShares DJ Brookfield Global Infrastructure ETF (TOLZ), the first ETF providing "pure-play" exposure to infrastructure.

ProShares High Yield--Interest Rate Hedged ETF Surpasses $100 Million in Assets
Business Wire - Wed Mar 19, 7:30AM CDT
ProShares, a premier provider of alternative exchange traded funds, today announced that its High Yield--Interest Rate Hedged ETF (HYHG) has garnered more than $100 million in assets since its launch in May 2013. HYHG delivers a portfolio of high yield bonds and a built-in interest rate hedge.

ProShares S&P 500 Aristocrats ETF Surpasses $100 Million
Business Wire - Thu Feb 27, 10:24AM CST
ProShares, a premier provider of alternative exchange traded funds, today announced that its S&P 500 Aristocrats ETF (NOBL) has gathered more than $100 million in assets since its October 2013 launch. NOBL is the only ETF or mutual fund that invests in the S&P 500 Dividend Aristocrats, an index composed of the S&P 500 companies that have increased their dividends year over year for at least 25 consecutive years.

Terra Nova Royalty Has Returned 11.2% Since SmarTrend Recommendation (TTT)
Comtex SmarTrend(R) - Tue Feb 04, 9:27AM CST
SmarTrend identified a Downtrend for Terra Nova Royalty (NYSE:TTT) on January 13th, 2014 at $86.85. In approximately 3 weeks, Terra Nova Royalty has returned 11.21% as of today's recent price of $77.11.

ProShares Announces ETF Share Splits and Reverse Splits
Business Wire - Fri Jan 10, 2:59PM CST
ProShares, a premier provider of alternative ETFs, announced today share splits and reverse share splits on the ETFs listed below. The splits and reverse splits will not change the value of a shareholder's investment.

Terra Nova Royalty Shares Up 38.4% Since SmarTrend's Buy Recommendation (TTT)
Comtex SmarTrend(R) - Wed Aug 28, 11:02AM CDT
SmarTrend identified an Uptrend for Terra Nova Royalty (NYSE:TTT) on May 7th, 2013 at $66.70. In approximately 4 months, Terra Nova Royalty has returned 38.37% as of today's recent price of $92.29.

Uptrend Call Working As Terra Nova Royalty Stock Rises 50.8% (TTT)
Comtex SmarTrend(R) - Wed Aug 21, 9:41AM CDT
SmarTrend identified an Uptrend for Terra Nova Royalty (NYSE:TTT) on May 7th, 2013 at $66.70. In approximately 4 months, Terra Nova Royalty has returned 50.81% as of today's recent price of $100.59.

Uptrend Call Working As Terra Nova Royalty Stock Rises 41.5% (TTT)
Comtex SmarTrend(R) - Wed Aug 14, 9:14AM CDT
SmarTrend identified an Uptrend for Terra Nova Royalty (NYSE:TTT) on May 7th, 2013 at $66.70. In approximately 3 months, Terra Nova Royalty has returned 41.45% as of today's recent price of $94.35.

Uptrend Call Working As Terra Nova Royalty Stock Rises 37.6% (TTT)
Comtex SmarTrend(R) - Tue Aug 06, 4:46PM CDT
SmarTrend identified an Uptrend for Terra Nova Royalty (NYSE:TTT) on May 7th, 2013 at $66.70. In approximately 3 months, Terra Nova Royalty has returned 37.65% as of today's recent price of $91.81.

Terra Nova Royalty Up 33.4% Since SmarTrend Uptrend Call (TTT)
Comtex SmarTrend(R) - Tue Jul 30, 11:12AM CDT
SmarTrend identified an Uptrend for Terra Nova Royalty (NYSE:TTT) on May 7th, 2013 at $66.70. In approximately 3 months, Terra Nova Royalty has returned 33.37% as of today's recent price of $88.96.

Terra Nova Royalty Has Returned 29.8% Since SmarTrend Recommendation (TTT)
Comtex SmarTrend(R) - Tue Jul 23, 10:17AM CDT
SmarTrend identified an Uptrend for Terra Nova Royalty (NYSE:TTT) on May 7th, 2013 at $66.70. In approximately 3 months, Terra Nova Royalty has returned 29.81% as of today's recent price of $86.58.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innovent's SINTBILO® Hits Primary Endpoint in Study

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Webull Faces Class Action Suit: Key Deadlines Loom

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Novo's Semaglutide Shows Promise in MASH Study

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

MWC26 Doha: Bridging Standards for MENA's Future

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

LG's ASIL D Certification: A Game Changer in Autos

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

GlycoNex Eyes Japanese Market with Denosumab Biosimilar

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

CureGene's Evategrel Aims for Breakthrough in Stroke Care

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...